231 related articles for article (PubMed ID: 15999409)
1. Psychiatry has effectively become a commodity that is being sold to the drug industry.
Timimi S
Ment Health Today; 2005 Jun; ():21. PubMed ID: 15999409
[No Abstract] [Full Text] [Related]
2. Big pharma and American psychiatry.
Sharfstein SS
J Nerv Ment Dis; 2008 Apr; 196(4):265-6. PubMed ID: 18414119
[No Abstract] [Full Text] [Related]
3. Both sides of pharmaceutical promotion.
Crigger NJ; Bennison LW
Adv Nurse Pract; 2007 Jan; 15(1):61-2, 64-5, 74. PubMed ID: 19998677
[No Abstract] [Full Text] [Related]
4. Why self-regulation does not work: resolving prescription corruption caused by excessive gift-giving by pharmaceutical manufacturers.
Mehta RS
Food Drug Law J; 2008; 63(4):799-821. PubMed ID: 19593922
[No Abstract] [Full Text] [Related]
5. Risky business.
Ment Health Today; 2005 May; ():12-3. PubMed ID: 15938578
[No Abstract] [Full Text] [Related]
6. 'Big pharma' and psychiatry: 'the devil is in the dyad'.
Anand S
Aust N Z J Psychiatry; 2012 Dec; 46(12):1118-9. PubMed ID: 23212138
[No Abstract] [Full Text] [Related]
7. Industry-to-physician marketing and the cost of prescription drugs.
Chiong W
Am J Bioeth; 2003; 3(3):W28-W29. PubMed ID: 14594480
[No Abstract] [Full Text] [Related]
8. Drug companies and clinical psychology.
Baker E; Newnes C; Myatt H
Ethical Hum Sci Serv; 2003; 5(3):247-53. PubMed ID: 15139338
[TBL] [Abstract][Full Text] [Related]
9. Pharmaceuticals and medical devices: business practices. End-of-year issue brief.
Jones TM
Issue Brief Health Policy Track Serv; 2008 Jan; ():1-32. PubMed ID: 18345554
[No Abstract] [Full Text] [Related]
10. The ethics of advertising strategies in the pharmaceutical industry.
Reuter L
Ethics Med; 2003; 19(3):171-5. PubMed ID: 14700051
[No Abstract] [Full Text] [Related]
11. [Psychiatrists and the pharmaceutical industry].
Helmchen H
Nervenarzt; 2003 Nov; 74(11):955-64. PubMed ID: 14694885
[TBL] [Abstract][Full Text] [Related]
12. Dangerous liaisons?
Legge A
Nurs Times; 2000 Jun 22-28; 96(25):30-1. PubMed ID: 11962979
[No Abstract] [Full Text] [Related]
13. Disease management. What happened to the unlikely lads.
O'Connell N
Health Serv J; 2000 May; 110(5706):suppl 6, 8. PubMed ID: 11183792
[No Abstract] [Full Text] [Related]
14. Pharmaceutical industry influences on physician prescribing: gifts, quasi-gifts, and patient-directed gifts.
Berger JT
Am J Bioeth; 2003; 3(3):56-7. PubMed ID: 14594495
[No Abstract] [Full Text] [Related]
15. Banning pens and pads misses the main point.
Terry SF; Burke W
Am J Bioeth; 2003; 3(3):63-5. PubMed ID: 14594500
[No Abstract] [Full Text] [Related]
16. Medicine's Leveson.
Spence D
BMJ; 2012 Mar; 344():e1671. PubMed ID: 22399709
[No Abstract] [Full Text] [Related]
17. Pharmaceutical industry guide. Strange bedfellows?
Moore A
Health Serv J; 2002 Nov; 112(5833):suppl 13-5. PubMed ID: 12478712
[No Abstract] [Full Text] [Related]
18. Pharmaceuticals and medical devices: business practices.
Jones TM
Issue Brief Health Policy Track Serv; 2009 Jan; ():1-54. PubMed ID: 19297719
[No Abstract] [Full Text] [Related]
19. Who pays the piper?
Friedli L
Ment Health Today; 2003 Nov; ():8-9. PubMed ID: 14689593
[No Abstract] [Full Text] [Related]
20. When Does FDAMA Section 114 Apply? Ten Case Studies.
Neumann PJ; Saret CJ
Value Health; 2015 Jul; 18(5):682-9. PubMed ID: 26297097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
